Table 10 Stability study of optimized primaquine-loaded transdermal patch formulation (F5)
From: Primaquine-loaded transdermal patch for treating malaria: design, development, and characterization
Time | Temp | % Drug content | Transparency | pH | Folding endurance (Numbers) | Tensile Strength (Kg/cm2) | % Elongation | % Moisture content |
|---|---|---|---|---|---|---|---|---|
1 Day | 4 °C | 99.70 ± 0.4 | Y | 5.4 ± 0.1 | 188 ± 6 | 0.43 ± 0.015 | 37.9 ± 0.12 | 06.75 ± 0.04 |
25 °C | 99.70 ± 0.0 | Y | 5.5 ± 0.1 | 190 ± 8 | 0.41 ± 0.014 | 38.6 ± 0.19 | 06.83 ± 0.03 | |
40 °C | 99.70 ± 0.1 | Y | 5.4 ± 0.2 | 185 ± 6 | 0.42 ± 0.013 | 37.6 ± 0.15 | 06.76 ± 0.05 | |
1 Month | 4 °C | 99.66 ± 0.3 | Y | 5.5 ± 0.1 | 189 ± 7 | 0.41 ± 0.010 | 37.9 ± 0.16 | 06.79 ± 0.06 |
25 °C | 99.60 ± 0.2 | Y | 5.4 ± 0.2 | 193 ± 6 | 0.42 ± 0.009 | 37.4 ± 0.10 | 06.71 ± 0.05 | |
40 °C | 99.59 ± 0.2 | Y | 5.5 ± 0.1 | 191 ± 8 | 0.43 ± 0.014 | 38.5 ± 0.12 | 07.71 ± 0.04 | |
2 Months | 4 °C | 99.53 ± 0.1 | Y | 5.4 ± 0.2 | 189 ± 9 | 0.42 ± 0.015 | 38.3 ± 0.17 | 07.74 ± 0.06 |
25 °C | 99.58 ± 0.4 | Y | 5.5 ± 0.1 | 194 ± 8 | 0.42 ± 0.014 | 38.0 ± 0.11 | 06.78 ± 0.05 | |
40 °C | 99.55 ± 0.3 | Y | 5.4 ± 0.1 | 187 ± 8 | 0.43 ± 0.014 | 38.7 ± 0.15 | 06.73 ± 0.04 | |
3 Months | 4 °C | 99.54 ± 0.2 | Y | 5.6 ± 0.2 | 186 ± 9 | 0.42 ± 0.015 | 38.1 ± 0.16 | 07.74 ± 0.05 |
25 °C | 99.54 ± 0.3 | Y | 5.5 ± 0.1 | 190 ± 8 | 0.42 ± 0.012 | 37.6 ± 0.10 | 07.73 ± 0.03 | |
40 °C | 99.51 ± 0.5 | Y | 5.5 ± 0.1 | 193 ± 9 | 0.42 ± 0.014 | 38.3 ± 0.12 | 07.75 ± 0.04 |